NDAORALCAPSULE, EXTENDED RELEASE
Approved
May 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
CONZIP (tramadol hydrochloride) by Cipher Pharmaceuticals is extended-release capsules contain tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. Approved for pain, low back pain, osteoarthritis and 4 more indications. First approved in 2010.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONZIP is an extended-release oral capsule containing tramadol hydrochloride, a dual-action opioid agonist and norepinephrine/serotonin reuptake inhibitor approved in 2010. It treats acute and chronic pain conditions including low back pain, osteoarthritis, diabetic neuropathy, and fibromyalgia. The drug's analgesic effect derives from both the parent compound and its M1 metabolite binding to mu-opioid receptors, complemented by monoamine reuptake inhibition.
$0.042MPart D
LOE ApproachingDeclining
Minimal commercial activity with only $42K in Part D spending and 58 claims in 2023 signals a mature, low-volume product nearing end-of-life with limited team growth opportunities.
Mechanism of Action
Extended-Release Capsules contain tramadol, an opioid agonist, and an inhibitor of reuptake of norepinephrine and serotonin. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to…
Indications (7)
Worked on CONZIP at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.